Want to see JP:4892 full AI Analyst Report?

Cyfuse Biomedical K.K. (4892) Price & Analysis

0 Followers

4892 Stock Chart & Stats

¥590.00

¥1.00(0.23%)

At close: Jan 08 4:00 PM EST

¥590.00

¥1.00(0.23%)

Day’s Range― - ―

52-Week Range¥487.00 - ¥764.00

Previous CloseN/A

Volume38.50K

Average Volume (3M)63.70K

Market Cap

¥5.74B

Enterprise Value¥3.38B

Total Cash (Recent Filing)¥3.39B

Total Debt (Recent Filing)¥1.23B

Price to Earnings (P/E)―

Beta0.33

Next Earnings

Nov 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-81.38

Shares Outstanding10,092,100

10 Day Avg. Volume26,570

30 Day Avg. Volume63,696

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)1.88

Price to Sales (P/S)22.48

P/FCF Ratio-8.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue ReboundThe substantial 2025 revenue rebound indicates renewed commercial activity for the company’s regenerative-medicine technology and related offerings. If this growth is sustained, a larger revenue base could improve operating leverage, support customer adoption, and provide a foundation for future scale.

Positive Gross MarginA positive gross margin shows that the company’s offerings generate contribution above direct costs, despite the current operating losses. This provides an underlying economic base from which improved utilization, pricing, or cost discipline could eventually support better profitability as revenue expands.

Manageable LeverageDebt-to-equity below 0.5 and a sizable equity base indicate that leverage is not yet excessive relative to the company’s assets. This balance-sheet position provides some capacity to continue developing its technology and pursuing growth while reducing immediate solvency pressure.

Bears Say

Deep Operating LossesExtremely negative operating and net margins show that the current cost structure is far too large for the company’s revenue base. Persistent losses can erode equity, restrict strategic flexibility, and make sustainable profitability dependent on substantial execution and operating improvements.

Persistent Cash BurnRepeatedly negative operating and free cash flow indicate that the business does not yet fund its operations internally, even after the revenue rebound. Continued cash burn increases reliance on external capital and leaves less financial capacity for research, commercialization, or unexpected setbacks.

Rising Debt Amid LossesThe increase in debt while the company remains deeply unprofitable raises financing dependence and could increase pressure on future capital allocation. If losses persist, additional borrowing may become more difficult or costly, while ongoing obligations can further constrain investment in growth.

4892 FAQ

What was Cyfuse Biomedical K.K.’s price range in the past 12 months?

Cyfuse Biomedical K.K. lowest stock price was ¥487.00 and its highest was ¥764.00 in the past 12 months.

What is Cyfuse Biomedical K.K.’s market cap?

Cyfuse Biomedical K.K.’s market cap is ¥5.74B.

When is Cyfuse Biomedical K.K.’s upcoming earnings report date?

Cyfuse Biomedical K.K.’s upcoming earnings report date is Nov 13, 2026 which is in 17 days.

How were Cyfuse Biomedical K.K.’s earnings last quarter?

Cyfuse Biomedical K.K. released its earnings results on Aug 14, 2026. The company reported -¥20.9 earnings per share for the quarter.

Is Cyfuse Biomedical K.K. overvalued?

According to Wall Street analysts Cyfuse Biomedical K.K.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cyfuse Biomedical K.K. pay dividends?

Cyfuse Biomedical K.K. does not currently pay dividends.

What is Cyfuse Biomedical K.K.’s EPS estimate?

Cyfuse Biomedical K.K.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cyfuse Biomedical K.K. have?

Cyfuse Biomedical K.K. has 10,092,100 shares outstanding.

What happened to Cyfuse Biomedical K.K.’s price movement after its last earnings report?

Cyfuse Biomedical K.K. reported an EPS of -¥20.9 in its last earnings report. Following the earnings report the stock price went up 1.633%.

Which hedge fund is a major shareholder of Cyfuse Biomedical K.K.?

Currently, no hedge funds are holding shares in JP:4892

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cyfuse Biomedical K.K.

Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.